Biocom California’s Post

Cutting-edge advancements in Generative AI and next generation computing are transforming the life sciences industry – this is not a traditional technology upgrade.   Accenture’s latest insights highlight five key imperatives for C-suite leaders, emphasizing the need for end-to-end reinvention. By integrating AI across the pharmaceutical value chain, companies can reduce the time to market for new medicines, increase revenues, and cut costs. This piece explores how AI can fuel innovation, build resilient supply chains, and ultimately enhance patient outcomes. The future of life sciences is being redefined by intelligent technologies.   #lifesciences #GenAI

🌟 Revolutionizing Life Sciences with UBIX.AI AI 🌟 At UBIX.AI, we're not just embracing the future of AI—we're building it. 🚀 For life sciences organizations, the journey to groundbreaking innovations in pharmaceuticals, biotechnology, and healthcare is filled with challenges: vast biological data, lengthy clinical trials, and complex regulatory landscapes. This is where UBIX.AI’s Intelligent Cloud changes the game. From genomic sequencing to clinical trial optimization, our solutions empower life sciences companies to uncover insights with unmatched speed and precision. Imagine: ✅ Accelerated drug discovery ✅ Enhanced clinical trials ✅ Innovations in personalized medicine ✅ Predictive analytics for R&D ✅ Streamlined regulatory compliance AI isn’t just a tool—it’s the catalyst for transforming patient outcomes and reshaping the life sciences industry. Ready to embrace the next frontier of innovation? Discover how UBIX.AI is driving efficiency and breakthroughs across the life sciences landscape. 👉 Learn more at www.ubixlabs.com #AI #healthcare #clinical #analytics

🧬 The Convergence of Artificial Intelligence and Biological Sciences: A Transformative Era A critical analysis of the emerging biotechnology landscape reveals a paradigm shift in how we approach medical innovation. According to a recent McKinsey's comprehensive analysis, generative AI technologies present a $60B-$110B annual opportunity in pharmaceutical applications - a testament to the profound transformation underway in our field. 🔬 Through our efforts investing at Builders VC, we've identified exemplary cases of this technological integration: - Our investment has helped Arpeggio Bio develop a sophisticated platform analyzing cellular transcription mechanisms, advancing our understanding of previously intractable therapeutic targets. - Our investment in Pathos AI's has enabled an innovative approach to precision oncology demonstrating the practical application of AI in clinical settings, optimizing patient selection protocols and accelerating therapeutic development. 📊 The promise of Generative AI is: • 50% reduction in drug discovery timelines • Clinical trial efficiency increased by 10%, with 50% cost optimization • Manufacturing deviation reduction of 30-40% • 5-10% enhancement in patient therapeutic adherence 🎯 A crucial observation: AI models constitute merely 15% of successful implementation. The fundamental challenge lies in developing robust data architecture and reimagining systematic workflows - drawing parallels to the transformative integration of electricity in 20th-century industries. 💡 Our thesis and belief indicates that the synthesis of artificial intelligence, biological sciences, and clinical data analytics represents a pivotal moment in healthcare evolution. We focus our academic and practical efforts on supporting innovations that address these complex intersections. The biological revolution demands immediate, thoughtful engagement from the scientific community. Today's strategic decisions will shape the trajectory of innovation for generations to come. #BiomedicalScience #ArtificialIntelligence #ClinicalInnovation #BiotechnologyResearch #BuildersVC #TechBio #VentureCapital Builders VC Pathos Arpeggio Biosciences Joey Azofeifa Ryan Fukushima Eric Lefkofsky Jim Kim Mark Blackwell Further discourse welcome. 📚🧫

📈 Pharma R&D ROI Rebounds: The Power of AI 📈 The impact of AI reaches much further than one might think. After years of decline, pharma R&D ROI jumped to 4.1% in 2023, up from a record low of 1.2% in 2022. 🔍 AI’s Role in Drug Development AI is transforming R&D by predicting disease biology, streamlining trials, and front-loading attrition to filter low-quality candidates earlier. This leads to faster, cost-effective trials and more successful late-stage assets. 📊 Accelerated Innovation AI and data science reduce trial timelines and costs, with Deloitte and IQVIA confirming that AI-driven efficiencies are reshaping R&D and boosting ROI. AI is driving pharma’s future by making innovation faster, more efficient, and impactful. #Pharma #Innovation #Analytics #DataSciencr #AI #Deloitte #IQVIA

Following extensive research within our community, the Lab of the Future Congress Europe 2024 includes case studies and use cases from exciting biopharma experts, insightful sessions on collaborative research partnerships, and discussions on how to address the challenges of onboarding novel technologies in research, development, and manufacturing. The multi-track program is focused on the following themes: -       AI to Innovate -       AI to Optimize -       Supporting the Biotechs of the Future -       Connected Lab -       Automated Lab -       Digital Transformation -       Data Strategy -       Lab Operational Excellence Learn more here:  https://lnkd.in/exU8kGHB #labofthefuture #ai #digitaltransformation #lotfeu2024

One musing post JPM- The “TechBio” label needs to go. Over the years, the convergence of technology and biology has driven amazing innovations. But now the term “TechBio” seems to misrepresent the companies that are building the future of our industry. In our latest blog, by Chris Picardo and I: + todays “techbio” founders are driving towards cracking life science's hardest problems NOT chasing buzzwords + Why AI and data are essential for modern biotech + How differentiated datasets create that competitive edge At Madrona, we are partnering with visionary founders to build the platforms powering the next wave of biotech breakthroughs. If you're an entrepreneur building at the intersection of biotech and AI, love your take: Do we ditch “techbio” or embrace it? https://lnkd.in/gFCDCaQA

EXCLUSIVE: I've just listened to an insightful conversation with Demis Hassabis at FT Live, and it was packed with vision and direction for AI in drug discovery! Here’s what’s next, according to Hassabis: 🔹 AlphaFold2 marked a turning point in predicting protein structures, but AlphaFold3 steps up the game by tackling complex molecular dynamics, including RNA, DNA, and ligand interactions. Hassabis envisions an ambitious goal—a “virtual cell” model, allowing simulations of cellular processes to aid drug discovery. Realistic ETA? Around a decade. 🔹 Unlike many biotechs, Isomorphic Labs has opted not to build its own wet labs. Instead, Hassabis and his team are laser-focused on maximizing data efficiency and algorithmic innovation. The lab-in-the-loop concept stands out, where existing data is pushed to new limits with synthetic data, advancing AI model sophistication without the usual lab setup. 🔹 Developing accurate, AI-driven toxicity and safety predictions remains challenging due to limited historical data. However, Isomorphic Labs is actively exploring ways to “fill in the gaps” with generated and bespoke data, aiming to boost preclinical predictiveness. 🔹 With partnerships at Novartis and Eli Lilly, Isomorphic Labs gains valuable, experimental data access, which it combines with its AI-driven models. This partnership approach lets the company focus on tough-to-crack problems—e.g., “undruggable” targets. 🔹 Hassabis highlighted the essential balance between open science and biosecurity, especially as AI tools become more powerful and adaptable. The goal is to ensure responsible use without stifling innovation. Exciting times ahead as AI continues to reshape biopharma. Hassabis’s “cautious optimism” serves as a reminder of the balance needed as these advancements progress. Can't wait to see how this all unfolds! What do you think? #FTPharma

Aquillius and ThinkingNode Life Science, Inc. 𝗝𝗼𝗶𝗻 𝗙𝗼𝗿𝗰𝗲𝘀 𝘁𝗼 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝘄𝗶𝘁𝗵 𝗔𝗜! On May 28th, we're proud to unveil a groundbreaking partnership at our 𝗔𝗜𝗗𝗕𝗜𝗢 𝗖𝗼𝗿𝗲 event. This collaboration unites Aquillius' expertise with TNL's industry-leading AI Digital Cell technology to significantly accelerate drug discovery and development. 𝗪𝗵𝗮𝘁 𝗶𝘀 𝗧𝗡𝗟? Imagine testing new drugs on human cells in hours, not years! TNL's innovative platform utilizes AI to generate digital clones of human cells. These "digital cell clones" act just like their real counterparts, allowing scientists to predict how drugs will interact with them before ever needing real people or animals. 𝗪𝗵𝘆 𝗶𝘀 𝘁𝗵𝗶𝘀 𝗮 𝗴𝗮𝗺𝗲-𝗰𝗵𝗮𝗻𝗴𝗲𝗿? TNL's AI Digital Cell technology offers a multitude of benefits for researchers and drug developers: 🔹 𝗙𝗮𝘀𝘁𝗲𝗿 𝗗𝗿𝘂𝗴 𝗧𝗲𝘀𝘁𝗶𝗻𝗴: Reduce the time it takes to test new drugs by using digital cells. 🔸𝗥𝗲𝗱𝘂𝗰𝗲𝗱 𝗖𝗼𝘀𝘁𝘀: Reduce the need for expensive and time-consuming animal testing, saving significant resources. 🔹 𝗜𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝗔𝗰𝗰𝘂𝗿𝗮𝗰𝘆: Gain a deeper understanding of how drugs will affect human cells, leading to the development of more effective treatments with fewer side effects. 🔸𝗡𝗼𝘃𝗲𝗹 𝗧𝗮𝗿𝗴𝗲𝘁 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆: Identify new targets for treating diseases, potentially leading to breakthroughs in previously difficult areas. 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗮𝘁 𝗔𝗜𝗗𝗕𝗜𝗢 𝗖𝗼𝗿𝗲 𝗼𝗻 𝗠𝗮𝘆 𝟮𝟴𝘁𝗵! Don't miss this presentation where we'll explore the science behind TNL and its advantages over traditional methods. We'll also showcase real-world examples of how TNL is being used to develop new drugs and how you can leverage this technology to streamline your R&D process. 𝗕𝗲 𝗮𝘁 𝘁𝗵𝗲 𝗳𝗼𝗿𝗲𝗳𝗿𝗼𝗻𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗳𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆! 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗳𝗼𝗿 𝗔𝗜𝗗𝗕𝗜𝗢 𝗖𝗼𝗿𝗲 𝘁𝗼𝗱𝗮𝘆! https://lnkd.in/geKZ_gHC #sandiego #ai #digitalbiology #AIDBioCore #innovation Khai Minh Pham MD, PhD (AI) MyPhuong Le, PhD Leah Villegas, PhD, MBA Aquillius Ventures California Life Sciences (CLS) Biocom California Women In Bio-Southern California

AI and Data in Pharma Healthcare Community in Munich adesso Life Sciences team has the privilege to participate in the AI and Data in Pharma Healthcare Summit, held on April 18-19, 2024. The event is bringing together approximately 200 participants from the Life Sciences and MedTech sectors for engaging discussions and expert conversations on various pertinent topics: • AI accelerating Drug Discovery • New Generation Self-service Data Platforms • Challenges in Real World Data • Large-language models – GenAI in Pharma • Why Data Engineering can be more important than Data Science • Data Monetization • Data Driven Insights and Decision making in Pharma and Healthcare • AI to precise Gene Editing • New ML Dataset for Structure-based Drug Discovery • Leveraging AI at the Frontline and Operations • Generative AI powering Patient Engagement It's an excellent opportunity for exchange and networking, fostering collaborations beyond the event itself. Such initiatives contribute significantly to the advancement of the Life Sciences ecosystem, ensuring collective progress in these innovative domains. #AdessoLifeSciences #AIinPharma #HealthcareSummit #LifeSciencesTech #MedTech #DataScience #ArtificialIntelligence #DrugDiscovery #RealWorldData #DataEngineering #PatientEngagement #MLinPharma"

Results Over Hype The real value of AI lies in its ability to deliver tangible results, not just bold promises. Here are some examples for change in healthcare AI today: 🔹 Proprietary Data as a Differentiator Companies like A-Alpha Bio and Vivodyne are proving that success in AI isn’t just about algorithms—it’s about the data. A-Alpha Bio’s proprietary protein-protein interaction database and Vivodyne’s lab-grown human tissues are unlocking insights traditional methods can’t match. 🔹 Focused Solutions, Not Overpromises DeepCure demonstrates that specificity beats sweeping claims. By targeting complex biological challenges with AI-driven drug discovery, they’re delivering real-world results where others are still talking potential. 🔹 The Power of Cross-Disciplinary Teams insitro is a prime example of how multidisciplinary expertise creates meaningful change. Their integration of machine learning and biology has attracted partnerships with Gilead Sciences and Bristol Myers Squibb, as well as $400 million in funding, showcasing their ability to bridge AI and drug discovery. 🔹 Strategic Integration with Industry Giants Owkin collaboration with pharmaceutical leaders like Sanofi and Bristol Myers Squibb highlights the importance of working within the healthcare ecosystem. With a $180 million investment from Sanofi, Owkin achieved unicorn status, proving their AI-driven oncology research is more than just hype. What approaches do you think will drive the biggest breakthroughs in the next two years? Let’s discuss. #HealthcareAI #DrugDiscovery #PharmaInnovation #AIInHealthcare #FutureOfHealthcare